Market Intelligence Index Tracks 100+ Peptide Vendors and 112,000 Public COA Records

A market intelligence index for the research peptide industry now catalogs more than 100 vendors, over 3,200 product listings and a corpus in excess of 112,000 public certificates of analysis, according to an industry announcement this month. It is among the broadest public snapshots yet of a market that has long run on word of mouth and forum threads.

What Happened

The index aggregates vendor listings, pricing ranges and public COA records into a searchable interface, with the stated goal of price and quality transparency across a fragmented market of resellers operating to very different standards.

The COA corpus is the most consequential piece. Certificates of analysis are posted voluntarily by vendors; aggregating 112,000+ of them lets buyers check whether a supplier's testing documentation is consistent over time — or absent entirely.

Who Is Affected

Buyers gain a starting point for comparing suppliers on documentation, not just price. Vendors with clean testing records get a differentiation channel that unverified competitors cannot fake. Vendors with gaps in their COA history face growing visibility, because aggregation makes missing documentation obvious. Researchers ultimately benefit from pricing discipline and clearer expectations across the market.

Timeline

• 2023–2025: The vendor landscape fragmented; forums and review sites became the default comparison tools.
• 2025: Independent labs expanded testing capacity and buyers began treating batch-specific COAs as standard practice.
• Early 2026: Aggregation projects began indexing public COA records at scale.
• September 2026: A market intelligence index spanning 100+ vendors and 112,000+ COA records goes public.

What This Means for Researchers

Aggregated data is context, not verification. A price index tells you what the market charges; a COA archive tells you what vendors have claimed — neither confirms what is inside the vial you receive. Use the index to shortlist suppliers with consistent public documentation, then verify the actual batch with a batch-specific COA or independent testing.

Watch for survivorship effects as well: a vendor that posts COAs selectively will look better in aggregate than its full history warrants. Consistency across batches and across time matters more than a handful of strong results.

How to Evaluate Vendors and Products

• Compare suppliers on documentation consistency, not just listed purity: vendor reviews and ratings
• Learn what a COA actually proves — and what it does not: how testing works
• Check the methods behind any purity claim: HPLC vs LC-MS
• Inspect physical quality markers including fill weight: identity, purity and fill weight
• Weigh price against quality using our vendor comparison tool

The Bottom Line

Transparency infrastructure in the peptide market is maturing quickly, and it raises the baseline for every participant. Aggregated indexes make it harder for undocumented sellers to hide — but the final check still belongs to the buyer, batch by batch.

Sources

Industry reports; company announcements; public COA archives.